Table 2. Relationship between PD-L1 protein expression and the clinicopathological feature.
| Clinicopathological feature | Studies | Heterogeneity | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| P value | I2 (%) | ||||
| Gender | 6 | 0.470 | 0 | 0.84 (0.59–1.18) | 0.31 |
| Differentiation | 5 | 0.100 | 48 | 1.33 (0.95–1.85) | 0.09 |
| Tumor depth | 5 | 0.010 | 70 | 0.66 (0.33–1.35) | 0.26 |
| Status of lymph node | 6 | <0.00001 | 85 | 0.67 (0.30–1.52) | 0.34 |
| Metastasis | 5 | 0.940 | 0 | 0.66 (0.40–1.09) | 0.10 |
| Stage | 5 | 0.005 | 73 | 0.93 (0.49–1.75) | 0.82 |
CI, confidence interval; PD-L1, programmed cell death ligand 1.